Oxford Nanopore appoints Peter Allen as Non-Executive Director
Oxford Nanopore Technologies Ltd is pleased to announce the appointment of Peter Allen ACA to its board.
Peter Allen joins the board of Oxford Nanopore as non executive Director with broad, senior experience in the life sciences industries. He currently serves as Non-Executive Chairman on the Boards of ProStrakan Group plc, Chroma Therapeutics Ltd and Proximagen Neuroscience plc.
Previously, Peter was Chief Financial Officer of the electronics company Abacus Group plc from April 2005 until the company was sold to Avnet Inc in January 2009. Prior to this he was Chief Financial Officer of Celltech Group plc between 1992 and 2004. In addition to managing Celltech's flotation process in 1993, Peter played a key role in several strategic acquisitions, including Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. In 2003 Peter was also appointed Deputy Chief Executive Officer of Celltech until the company was sold to UCB in 2004.
Oxford Nanopore also announces the retirement of Riccardo Pigliucci from his role as non executive director, after serving nearly five years on the board.
“We are excited to welcome Peter Allen to the Board of Oxford Nanopore,” said Dr Trevor Nicholls, Chairman of Oxford Nanopore. “Peter’s corporate and financial experience across science and technology industries will add to the strength of our existing board. We also extend our thanks to Riccardo Pigliucci for his years of valuable service to the Company.”
Dr Gordon Sanghera, CEO, added, “As Oxford Nanopore transitions to its next stage of corporate development, Peter will provide invaluable expertise along the pathway of a fast growth company with a genuinely disruptive technology. We are looking forward to working with Peter in this exciting period.”
Contact: Zoe McDougall, Communications, Oxford Nanopore
Oxford Nanopore Technologies
Oxford Nanopore Technologies Ltd is developing a novel technology for direct, electronic detection and analysis of single molecules using nanopores. The modular, scalable GridION technology platform is designed to offer substantial benefits in a variety of applications.
The Company is developing two techniques for DNA sequencing: Exonuclease Sequencing andStrand Sequencing, both of which combine a protein nanopore with a processive enzyme for the analysis of DNA. The system is also compatible with the direct analysis of RNA. Oxford Nanopore is also developing a Protein Analysis technology that combines target proteins with ligands for direct, electronic analysis using protein nanopores. These nanopore sensing techniques are combined with the Company's proprietary array chip within the GridION system. The Company also has collaborations for the development of solid-state nanopores.
Oxford Nanopore has collaborations and exclusive licensing deals with leading institutions including the University of Oxford, Harvard and UCSC. The Company has funding programmes in these laboratories to support the science of nanopore sensing. Oxford Nanopore has licensed or owns more than 300 patents and patent applications that relate to many aspects of nanopore sensing from protein nanopores to solid state nanopores and for the analysis of DNA, proteins and other molecules. This includes the use of functionalised solid-state nanopores for molecular characterisation, methods of fabricating solid-state nanopores and modifications of solid-state nanopores to adjust sensitivity or other parameters.